NAYA: מכפיל P/S NAYA Biosciences Corp

NAYA Biosciences is accelerating the search for cancer therapies by utilizing robotic cell analysis systems. High R&D expenditures and stringent FDA oversight, combined with unique antibody patents, create significant barriers to entry for competitors. The company's price/sales multiple, which currently stands at 0.30, demonstrates that valuation is dependent on clinical trial results and investment inflows.

To assess long-term risks, the investor utilizes the P/S ratio, calculated as the ratio of market capitalization to annual sales, which reflects the cost of each unit of revenue. When analyzing the price-to-sales chart, it should be noted that for NAYA Biosciences (NAYA), this metric is speculative in nature due to the lack of mass-market sales prior to the completion of clinical trials and the procurement of licenses.